History
Adocia is a French biotech company founded in 2005 by Gérard, Olivier and Rémi Soula with the goal of developing “innovative medicines for everyone, everywhere”.
History
A Story of Family Entrepreneurs
Adocia was founded in 2005 by Gérard Soula and his two sons Olivier and Rémi.
These three high-level scientists each had a PhD in polymer science and extensive experience in protein delivery. They also had one idea in mind: to take up the challenge of an innovative medicine for everyone in the world. They surrounded themselves with a team of highly qualified researchers and deigned the BioChaperone® technology.
Since its founding, Adocia has created innovations in several therapeutic domains based on its BioChaperone® technology, such as the healing of chronic wounds and the treatment of diabetes with insulin therapy.
Adocia,
a Sponge with Regenerative Properties
Among animal species, the sea sponge has the spectacular ability to regenerate its tissues following an injury.
This property allows it to survive the incessant attacks of fish.
Adocia is therefore a strong symbol for the company, which was at the very beginning dedicated to the regeneration of chronically and critically damaged tissue, one of the major comorbidities of patients suffering from diabetes.
Backed by years of experience in metabolic diseases, Adocia is moving closer to its ultimate goal: deliver “Innovative Medicines for Everyone, Everywhere”
In February 2012, Adocia was listed on the Euronext Paris market and raised €27 million.
A few years after, in 2017, Eli Lilly dedided to terminate the collaboration. Adocia regained full ownership of the rights that had been licensed at no cost.
This would enable this leader in insulin manufacturing in China to offer the fourth insulin generation to the Chinese patients.
This partnership expands the panel of potential partners for these same products in key markets such as the United States, Europe, and Japan.
Since 2019, the company has been combining hormones to treat diabetes and obesity (“diabesity”).
More recently, three new technology platforms were also added to Adocia patents portfolio, for cell therapy, oral delivery of peptides and long-acting formulation.
Adocia vocation is to accompany and relieve patients throughout their lives and to help them to manage their disease better.
The stylized silhouette of the artist Giacometti inspired us because it represents the patient on his way to recovery.
Adocia base line “Innovative Medicine for Everyone Everywhere” serves as a foundation and supports these men and women in their quest for a cure.